Summary

  • The US private equity industry’s record backlog of more than 13,500 unsold portfolio companies has concentrated regulatory pressure around portfolio-level disclosure rather than around any single transaction, with structural opacity functioning as the load-bearing variable beneath both critics’ extraction claims and the industry’s patient-capital defense.
  • PitchBook data cited by the Private Equity Stakeholder Project documents the inventory — 13,500+ unsold companies including 2,563 in consumer products and services and 1,536 in healthcare — alongside an industry footprint that employs more than 13 million US workers across retail, healthcare, and consumer brands.
  • Rosemary Batt, Brad Lipton, and Audrey Stienon attribute PE-backed bankruptcies to leverage and rising entry prices, while Edith Hotchkiss and Will Dunham of the American Investment Council counter that default rates track leverage generally and that committed capital can ride out downturns.
  • Senator Elizabeth Warren’s healthcare bill, the June housing bill, and the “Let Kids Play” Act have organized scrutiny along sector-specific lines, with Rosemary Batt identifying state and local initiatives as the most productive near-term action despite widely expected Democratic gains in November’s midterms.

The US private equity industry is sitting on a record inventory of more than 13,500 unsold portfolio companies, according to PitchBook data cited by the Private Equity Stakeholder Project, whose executive director Jim Baker said funds are sitting on a “record number of unsold companies, many of which they’ve been unable to sell … or at least unable to sell at the prices that they’re looking for.” Hundreds of those investments have been held years past typical fund timelines. The analytical center of the moment is not the backlog itself but the structural opacity beneath it: Brad Lipton, director of corporate power and financial regulation at the Roosevelt Institute, characterized the industry as one that operates “by design” in the shadows, in which “everything has to begin with the thought that we don’t have a lot of clarity.” That opacity is why congressional bills and state-level action have organized around disclosure rather than around any particular transaction, and why the same bankruptcy data is read, simultaneously and in good faith, as evidence of a market in transition and as a portfolio of stressed assets.

The scale: A 13-million-worker footprint with no portfolio-level data

PitchBook data cited by the Private Equity Stakeholder Project puts unsold inventory at more than 13,500 companies, including 2,563 consumer-products and services companies and 1,536 healthcare companies. PE firms and their portfolio companies employ more than 13 million people in the United States, according to the Private Equity Stakeholder Project, spanning the pet retailer PetSmart (owned by BC Partners); the footwear brand Birkenstock (purchased by L Catterton in 2021); and the kitchenware maker Pyrex (owned by Centre Lane Partners). Roark Capital’s holdings include Dave’s Hot Chicken, Two Men and a Truck, and School of Rock. PE investors have also bought thousands of healthcare facilities in recent years, including nonprofit hospice care, rural hospitals, and small-town dental offices.

The breadth of that footprint is the reason the disclosure gap matters beyond any single transaction: when a PE-backed employer fails, the loss lands on workers, patients, and municipalities rather than on the funds whose decisions produced the failure. Companies owned by PE generally do not report their debt levels or other financials unless they go public or issue bonds themselves — a feature Lipton’s “by design” formulation points to as a structural rather than incidental property of the industry.

The mechanism: Leverage plus entry-price inflation

Lipton compared PE deals to “buying a home with a mortgage — except the company itself, not the buyer, is on the hook for payments, and the buyer plans to sell within years.” Lipton added that “interest rates being unexpectedly high may have complicated exit strategies.” Edith Hotchkiss, a finance professor at Boston College, identified leverage as the strongest predictor of bankruptcy in the academic literature; PE-backed companies carry debt of about 50 percent of enterprise value, recent studies show. Hotchkiss also noted that PE default rates are no higher than those of other similarly levered firms — a finding that complicates the critics’ framing and pairs naturally with the industry’s patient-capital defense. If the patient-capital claim holds, it would predict exactly that convergence.

What has changed, according to Rosemary Batt, a Cornell University management and labor professor who studies the industry, is the price of buying target companies. Healthcare companies that once sold at roughly 11 times EBITDA now trade at 18 times or more, Batt said. Higher entry prices, combined with limited regulation of how PE firms treat their portfolios, are “putting even more pressure on PE firms to squeeze the juice out of their portfolio companies,” Batt said, “at a time when there’s almost no regulation governing how they do that.” Firms “can engage in financial engineering or just slash and burn on the operating side,” Batt added, “and it takes years for anyone to really see it.”

The failure data: Where the leverage problem has already landed

PE-backed companies accounted for the majority of large US corporate bankruptcies in 2025 and the first half of 2026, according to the Private Equity Stakeholder Project. More than 60 percent of large US manufacturing bankruptcies last year were PE-backed, Baker said, as were an outsized share of healthcare bankruptcies. Retailers Saks and Eddie Bauer filed for bankruptcy; Kmart, JoAnn Fabrics, and the hospital chain Steward Health Care have already collapsed, costing thousands of jobs and leaving several communities without a local hospital.

Audrey Stienon, industrial-policy program manager at the antimonopoly think tank Open Markets, said a growing concern is that “eventually, the companies that have accumulated this much debt are going to collapse.” PE-owned companies are often “really, really important businesses” providing jobs or vital services, Stienon said, so when they fail, “either you need to bail them out, or you need to find some to save them, or else you’re just stuck with fewer options for consumers down the line.”

Pablo Willis, a spokesman for Americans For Tax Fairness, warned that PE-owned rural hospitals and other healthcare-provider chains are “vulnerable” — particularly as Trump-administration cuts to Affordable Care Act tax credits and Medicaid “bite” — and that “there’s bound to be a very negative effect.” The ACA and Medicaid cuts function here as an exogenous policy stressor layered on top of the leverage problem, sharpening the public-health-framing stakes for rural and small-town providers already operating on thin margins.

The defense: Patient capital, no portfolio-level data of its own

Will Dunham, president and chief executive of the American Investment Council, said in a statement: “Private equity-backed businesses face the same higher interest rates and economic pressures as other companies, but they also have committed investment partners that can provide additional capital and keep investing through difficult periods. Ultimately, private equity only succeeds when the businesses it invests in succeed over the long term.”

That defense, like the critics’ extraction claim, runs without portfolio-level data of its own. The trade group’s standing assertion of long-run alignment cannot presently be confirmed or falsified, because companies owned by PE generally do not report their debt levels or other financials unless they go public or issue bonds themselves. The Hotchkiss caveat — comparable default rates under comparable leverage — fits here as well: if the patient-capital claim holds, it would predict exactly that convergence, and on the available record, the convergence is what the data show.

How the framings diverge on the same data

Mapping the positions present in the source material yields accounts that converge on the same underlying data — leverage levels, entry-price inflation, bankruptcy concentration, healthcare exposure — and part ways on what those data are evidence of:

  • An industry-aligned account, in the form articulated by the American Investment Council through Will Dunham, treats the present stress as a mark-to-market problem that exits will resolve, with patient capital providing committed investment across cycles; the standing claim is that “private equity only succeeds when the businesses it invests in succeed over the long term.”
  • An academic-and-watchdog account, advanced by Batt, Baker, Stienon, and the Private Equity Stakeholder Project, treats the model as one in which leverage and rising entry prices — driven in part by industry growth in fund count — produce pressure to generate returns through operational cuts or financial engineering.
  • A systemic-risk account, articulated by Lipton, Willis, and the Roosevelt Institute, foregrounds the opacity of the industry and the concentration of PE ownership in essential services, where failures produce costs that standard bankruptcy procedures do not internalize.
  • A public-health account, reflected in Warren’s bill and in the rural-hospital bankruptcies, treats PE ownership of care providers as a distinct mortality question separable from financial returns, with Trump-administration ACA and Medicaid cuts compounding the leverage exposure.
  • A labor account, implicit in the 13-million-worker employment figure and in Lipton’s pension formulation, treats the disclosure gap as a question of who bears the loss when a fund’s patience runs out.

None of the accounts has been displaced on the available record. Patient capital and debt-driven extraction are not, on present evidence, mutually exclusive — a fund can ride out one downturn and preside over a Steward-scale collapse in another, and the public cannot currently distinguish which kind of fund owns which hospital. When PE-backed companies do collapse, Lipton said, “by definition there is not enough money to go around to pay” their debts, and “someone is going to lose out and all too often that can be workers” owed pensions.

What happens next: The federal-state split

Congressional scrutiny of the industry has grown across party lines, even before the current interest-rate strain. A June housing bill curbs PE investment in single-family homes. Senator Elizabeth Warren, one of the industry’s most vocal critics in Washington, is leading a healthcare bill that would impose criminal penalties on “executives who loot health care entities like nursing homes and hospitals if that looting results in a patient’s death,” along with clawbacks of PE compensation. The “Let Kids Play” Act would ban PE from youth community sports, described in the bill as a “$40bn industry dominated by private equity, with the singular goal of extracting as much profit as possible from families.” The corporate law firm Holland & Knight warned this month that “for private equity, the question increasingly is not whether Congress will investigate private equity firms and their practices, but rather where the scrutiny will turn to next.”

November’s midterm elections are widely expected to deliver one or both chambers of Congress to Democrats, but Batt identified the “best opportunities right now” as “local and state level initiatives,” because Congress, even with a Democratic shift, will be “very hard pressed to do much.” Several states are pursuing their own rules. The federal-state split is, on Batt’s account, more than a temporary artifact of the legislative calendar; the locus of action is likely to remain at the state level until disclosure itself becomes federal. Whether Lipton’s “by design” formulation reflects firm-by-firm choice, decades of federal regulatory permission, or both is a question the substrate does not resolve.

The constituency that absorbs the difference

The disclosure gap is what keeps loss-absorption out of the discussion until after it has happened. Lipton’s formulation — “someone is going to lose out and all too often that can be workers” owed pensions — names the constituency that absorbs the difference between “market in transition” and “portfolio of stressed assets.” Each framing reads the same bankruptcy data differently and proposes a different fix; what holds across all of them is the disclosure requirement: portfolio-level debt, ownership, and operational data sufficient to test the industry’s patient-capital claim against the critics’ extraction claim before, not after, a Steward-scale collapse.

Additional considerations: Verification limits of the present record

The substrate is a single Guardian article dated 2026-09-04. Independent verification of the underlying PitchBook figures (more than 13,500 unsold companies; 2,563 consumer-products and services; 1,536 healthcare), the bankruptcy-share statistics (PE-backed majority of large US corporate bankruptcies in 2025 and H1 2026; more than 60 percent of large US manufacturing bankruptcies), and the 13-million-employees figure rests on the Private Equity Stakeholder Project’s own data and PitchBook citations as conveyed by the Guardian. The article does not link to a primary PitchBook dataset or PESP report, so the figures cannot be independently confirmed within this turn. Resolution would require direct access to the PESP report and the PitchBook dataset it cites.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Decision Clarity
Articulates the real stakes, stakeholders, and interests behind a decision facing a third party.
Dialectical Analysis
Holds thesis against antithesis and works toward a higher synthesis.
Worldview Cartography
Maps the clashing worldviews underlying a dispute.